Daidzein-rich isoflavone aglycones inhibit cell growth and inflammation in endometriosis

Publication date: July 2018Source: The Journal of Steroid Biochemistry and Molecular Biology, Volume 181Author(s): O. Takaoka, T. Mori, F. Ito, H. Okimura, H. Kataoka, Y. Tanaka, A. Koshiba, I. Kusuki, S. Shigehiro, T. Amami, J. KitawakiAbstractEndometriosis is an estrogen-dependent disease, and isoflavones interact with estrogen receptors. The purposes of this study are to investigate the in vitro and in vivo effects of daidzein-rich isoflavone aglycones (DRIAs), dietary supplements, on cellular proliferation in endometriosis. Stromal cells isolated from ovarian endometrioma (OESCs) and normal endometrium (NESCs) were cultured with DRIAs, i.e., each of the DRIA components (daidzein, genistein, or glycitein), or isoflavone glycosides (IG; DRIA precursors). A mouse model of endometriosis was established by transplanting donor-mouse uterine fragments into recipient mice. Our results showed that DRIAs (0.2–20 μM) inhibited the proliferation of OESCs (P 
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research

Related Links:

ConclusionBoth PRP and fibrin sealant appear to be safe and associated with improved tissue healing during shaving for the excision of colonic endometriosis, attributed to the enhanced collagen disposition, neovascularization, and protection of the integrity of colon layers. Clinical trials are warranted to confirm the feasibility of PRP and fibrin sealant in the clinical setting.
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
ConclusionBoth PRP and fibrin sealant appear to be safe and associated with improved tissue healing during shaving for the excision of colonic endometriosis, attributed to the enhanced collagen disposition, neovascularization, and protection of the integrity of colon layers. Clinical trials are warranted to confirm the feasibility of PRP and fibrin sealant in the clinical setting.
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
CONCLUSION: LEF could be a new therapeutic drug for EMS. PMID: 29714881 [PubMed - in process]
Source: Clinical and Experimental Obstetrics and Gynecology - Category: OBGYN Tags: Clin Exp Obstet Gynecol Source Type: research
In conclusion, DRIAs inhibit cellular proliferation in endometriosis, thus representing a potential therapeutic option for the management of endometriosis.
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
CONCLUSION: A 33-year-old woman developed pancytopenia during a course of fidaxomicin therapy for CDI. Platelet, hemoglobin, and WBC values returned to normal within 3 days of the final fidaxomicin dose. PMID: 29626003 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Tags: Am J Health Syst Pharm Source Type: research
CONCLUSION: Esmya, Duphaston and Dienogest are effective anti-endometriosis drugs targeting proliferation, apoptosis and adhesion. Esmya, Duphaston and Dienogest are all well tolerable, although endometrial glandular hyperplasia was found in Dienogest, endometrial atrophy in Duphaston, follicle accumulation in Esmya. PMID: 29615065 [PubMed - in process]
Source: Reproductive Biology - Category: Reproduction Medicine Authors: Tags: Reprod Biol Endocrinol Source Type: research
This study included comparison of IL-32 levels in the peritoneal fluids between women with and without endometriosis,in-vitro experiments using Ishikawa cells and endometrial stromal cells (ESCs), and experiments on IL-32 transgenic mice and wild-type mice with induced endometriosis.PARTICIPANTS/MATERIALS, SETTING, METHODSIL-32 levels in the peritoneal fluids were measured using enzyme-linked immunosorbent assays. Cell viability, expression of proliferating cell nuclear antigen (PCNA), and cellular invasiveness were analyzed followingin-vitro treatment of Ishikawa cells and ESCs with recombinant IL-32 alpha ( α) and ...
Source: Human Reproduction - Category: Reproduction Medicine Source Type: research
Abstract To analyze the role of PAI-1 (plasminogen activator inhibitor 1) in endometriotic lesion growth, we studied the effect of PAI-1 inhibition by PAI-039 using a homologous mouse model of endometriosis that allows non-invasive monitoring. Endometrial tissue from donor mice was collected, labeled with mCherry adenovirus, and implanted into a subcutaneous pocket on the ventral abdomen of recipient mice. Seven days after transplantation, mice were randomly allocated in two groups and treated once daily for two weeks with either vehicle (control group) or PAI-1 inhibitor (PAI-039 group). Endometriotic lesion size...
Source: Biology of Reproduction - Category: Reproduction Medicine Authors: Tags: Biol Reprod Source Type: research
This article is protected by copyright. All rights reserved.
Source: Stem Cells - Category: Stem Cells Authors: Tags: Tissue ‐Specific Stem Cells Source Type: research
.
Source: Gynecological Endocrinology - Category: Endocrinology Authors: Source Type: research
More News: Biochemistry | Biology | Complementary Medicine | Diets | Endometriosis | Molecular Biology | Nutrition | Ovaries | Soy isoflavones | Study | Transplants